NEWTOWN, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Avis Rent A Car System LLC (“Avis”). Avis learned of suspicious activity on or about August 5, 2024. To join this case, go HERE. About Avis Rent a Car System LLC Avis is an American car rental company headquartered in Parsippany-Troy Hills, New Jersey. What happened? On or about August 5, 2024, Avis discovered that hackers had accessed one of their business appli ...

PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend, subject to market and other customary conditions, to offer $500 million aggregate principal amount of senior notes due 2030 (the “Notes”) in a private offering. The Notes will be guaranteed on a senior unsecured basis by Avis Budget Group, Inc. and certain of ...

Group 1 - Murphy Law Firm is investigating claims related to a data breach involving Avis Rent A Car, which compromised personal and confidential information of individuals [1][2] - On August 5, 2024, Avis detected suspicious activity indicating a data breach, leading to a forensic investigation that revealed cybercriminals accessed sensitive data files [1] - The breach potentially exposed sensitive personal information of 299,006 individuals, including names and other personally identifiable information [1][2] Group 2 - The compromised information may be sold on the dark web or used for identity theft, prompting individuals to seek legal recourse [2] - Murphy Law Firm is evaluating legal options, including a potential class action lawsuit, to recover damages for affected individuals [2] - The firm specializes in data breach class actions and has a track record of securing favorable recoveries for clients [2]

Car rental giant Avis is notifying hundreds of thousands of people that their personal information and driver’s license numbers were stolen in an August cyberattack.The New Jersey-headquartered company said in a data breach notice filed with several U.S. attorneys general over the past week that it discovered intruders in one of its business applications on August 5 and took efforts to end the unauthorized access, which the company said began two days earlier.  Avis did not disclose the nature of the cyber ...

Core Viewpoint - CAPREIT has shown strong performance despite challenges in the Canadian real estate market, with a notable increase in stock price and positive financial results in Q2 2024 [6][7][20]. Financial Performance - CAPREIT reported a 5.4% increase in operating revenues, reaching CAD 278.1 million in Q2 2024 compared to CAD 263.8 million in Q2 2023 [15]. - Net income rose by 7.2% to CAD 186.3 million, with a net operating income (NOI) margin of 67.0% [15]. - The company achieved a 9.1% increase in funds from operations (FFO), amounting to CAD 109.1 million, with FFO per unit rising to CAD 0.644 [15]. Portfolio and Occupancy - CAPREIT's total portfolio consisted of 64,155 suites as of June 30, 2024, with a slight decrease from 64,260 suites at the end of 2023 [9]. - Occupancy rates dipped slightly to 97.7% across the total portfolio, down from 98.2% [9][10]. - The Canadian residential portfolio maintained a high occupancy rate of 98.2%, while the Netherlands portfolio occupancy was at 97.7% [9]. Rent Growth and Market Conditions - Monthly rents increased by 5% due to strong market conditions, despite low suite turnovers [10][12]. - CAPREIT has significant embedded value in its portfolio, with a mark-to-market opportunity in rents expected to be captured over the next 5-9 years [12][17]. Debt and Financing - CAPREIT completed mortgage financings totaling CAD 409.9 million with a weighted average interest rate of 4.51% and a term to maturity of 7.5 years [18]. - The company’s debt strategy remains conservative, with a total debt to gross book value ratio of 41.5% [13]. Dividend and Future Outlook - A 3% distribution hike was announced, increasing the annual distribution from CAD 1.45 to CAD 1.50 [20]. - The stock trades at approximately 19.6 times the 2025 FFO, indicating potential for further growth as NAV estimates may rise by 3%-5% over the next year [20][22].

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapyDemonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs SAN DIEGO, Sept. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from ...

Core Viewpoint - Anixa Biosciences is advancing its ovarian cancer CAR-T technology, specifically the chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) and is currently in a Phase 1 clinical trial [2][3][4]. Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at preventing triple negative breast cancer (TNBC) and ovarian cancer, along with other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. Technology Details - The CAR-T technology being developed by Anixa is an autologous cell therapy that utilizes engineered T cells to specifically target FSHR, which is present on granulosa cells of the ovaries [2]. - This innovative approach is referred to as CER-T therapy, distinguishing it from traditional CAR-T therapies due to its targeting of a hormone receptor [2]. Clinical Development - Dr. Jose R. Conejo-Garcia will present the ongoing Phase 1 clinical trial results at the upcoming Ovarian Cancer Research Symposium, highlighting the safety and tolerability of the treatment, with some patients showing signs of tumor necrosis [3].

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-genera ...

Rost-9D/iStock via Getty ImagesAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotech company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. ALLO uses advanced gene-editing platforms like TALEN and CRISPR/Cas9 to engineer donor-derived T cells. These off-the-shelf treatments overcome the limitations of autologous therapies by targeting and killing malignant cells. The company’s robust pipeline covers hematologic malignancie ...

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produc ...